Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120V3 signatures in the regulation of Co-Receptor usage

Retrovirology

Volumn 8, Issue , 2011, Pages

  Dimonte, Salvatore ^a   Mercurio, Fabio ^a   Svicher, Valentina ^a   D'Arrigo, Roberta ^b   Perno, Carlo Federico ^a,b   Ceccherini Silberstein, Francesca ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MEMBRANE PROTEIN; CXCR4 PROTEIN, HUMAN; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS RECEPTOR;

ALGORITHM; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BOOTSTRAPPING; CLUSTER ANALYSIS; CORRELATION COEFFICIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; VIRUS RESISTANCE; VIRUS STRAIN; DNA SEQUENCE; GENETICS; METABOLISM; MISSENSE MUTATION; PHYSIOLOGY; VIRAL TROPISM; VIRUS ATTACHMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MUTATION, MISSENSE; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; SEQUENCE ANALYSIS, DNA; VIRAL TROPISM; VIRUS ATTACHMENT;

EID: 79955820877     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-8-33     Document Type: Article

References (103)

1. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273. 10.1016/S0092-8674(00)80205-6, 9108481.
2. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-430. 10.1038/387426a0, 9163431.
3. Farzan M, Choe H, Desjardins E, Sun Y, Kuhn J, Cao J, Archambault D, Kolchinsky P, Koch M, Wyatt R, Sodroski J. Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. J Virol 1998, 72:7620-7625. 110020, 9696864.
4. Zhu P, Chertova E, Bess J, Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci USA 2003, 100:15812-15817. 10.1073/pnas.2634931100, 307650, 14668432.
5. Helseth E, Olshevsky U, Furman C, Sodroski J. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol 1991, 65:2119-2123. 240081, 2002555.
6. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958. 10.1126/science.272.5270.1955, 8658171.
7. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135-1148. 10.1016/S0092-8674(00)81313-6, 8674119.
8. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666. 10.1038/381661a0, 8649511.
9. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85:1149-1158. 10.1016/S0092-8674(00)81314-8, 8674120.
10. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673. 10.1038/381667a0, 8649512.
11. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G proteincoupled receptor. Science 1996, 272:872-877. 10.1126/science.272.5263.872, 8629022.
12. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187. 10.1038/384184a0, 8906796.
13. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384:179-183. 10.1038/384179a0, 8906795.
14. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888. 10.1126/science.280.5371.1884, 9632381.
15. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001, 70:777-810. 10.1146/annurev.biochem.70.1.777, 11395423.
16. York J, Nunberg JH. Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41. J Virol 2004, 78:4921-4926. 10.1128/JVI.78.9.4921-4926.2004, 387687, 15078976.
17. Jacobs A, Sen J, Rong L, Caffrey M. Alanine Scanning Mutants of the HIV gp41 Loop. J Biol Chem 2004, 280:27284-27288.
18. Cao J, Bergeron L, Helseth E, Thali M, Repke H, Sodroski J. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol 1993, 67:2747-2755. 237598, 8474172.
19. Berger EA. HIV entry and tropism. When one receptor is not enough. Adv Exp Med Biol 1998, 452:151-157.
20. Loftin LM, Kienzle MF, Yi Y, Lee B, Lee FH, Gray L, Gorry PR, Collman RG. Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry. Virology 2010, 402:135-148. 10.1016/j.virol.2010.03.009, 20381825.
21. Scarlatti G, Tresoldi E, Björndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyö EM, Lusso P. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997, 3:1259-1265. 10.1038/nm1197-1259, 9359702.
22. Yi Y, Isaacs SN, Williams DA, Frank I, Schols D, De Clercq E, Kolson DL, Collman RG. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism. J Virol 1999, 73:7117-7125. 104231, 10438797.
23. Yi Y, Shaheen F, Collman RG. Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes. J Virol 2005, 79:1480-1486. 10.1128/JVI.79.3.1480-1486.2005, 544090, 15650174.
24. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 1996, 2:1244-1247. 10.1038/nm1196-1244, 8898753.
25. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991, 253:71-74. 10.1126/science.1905842, 1905842.
26. Westervelt P, Gendelman HE, Ratner L. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci USA 1991, 88:3097-3101. 10.1073/pnas.88.8.3097, 51392, 2014229.
27. O'Brien WA, Koyanagi Y, Namazie A, Zhao JQ, Diagne A, Idler K, Zack JA, Chen IS. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 1990, 348:69-73. 10.1038/348069a0, 2172833.
28. Hoffman TL, Doms RW. HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol Membr Biol 1999, 16:57-65. 10.1080/096876899294760, 10332738.
29. Hung CS, Vander Heyden N, Ratner L. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol 1999, 73:8216-8226. 112839, 10482572.
30. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, Stanfield RL, Robinson J, Sodroski J, Wilson IA, Wyatt R, Bewley CA, Kwong PD. Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4. Science 2007, 317:1930-1934. 10.1126/science.1145373, 2278242, 17901336.
31. Nabatov AA, Pollakis G, Linnemann T, Kliphius A, Chalaby MI, Paxton WA. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate co-receptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 2004, 78:524-530. 10.1128/JVI.78.1.524-530.2004, 303404, 14671134.
32. Speck RF, Wehrly K, Platt EJ, Atchison RE, Charo IF, Kabat D, Chesebro B, Goldsmith MA. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 1997, 71:7136-7139. 192016, 9261451.
33. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JS, Harrigan PR. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005, 192:466-474. 10.1086/431519, 15995960.
34. Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. HIV-1 co-receptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006, 194:238-246. 10.1086/504693, 16779731.
35. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005, 191:866-872. 10.1086/428096, 15717260.
36. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM. HIV type 1 chemokine co-receptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007, 44:591-595. 10.1086/511035, 17243065.
37. Boyd MT, Simpson GR, Cann AJ, Johnson MA, Weiss RA. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol 1993, 67:3649-3652. 237718, 8497073.
38. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992, 66:1354-1360. 240857, 1738194.
39. Regoes RR, Bonhoeffer S. The HIV co-receptor switch: a population dynamical perspective. Trends Microbiol 2005, 13:269-277. 10.1016/j.tim.2005.04.005, 15936659.
40. Church JD, Huang W, Mwatha A, Toma J, Stawiski E, Donnell D, Guay LA, Mmiro F, Musoke P, Jackson JB, Parkin N, Eshleman SH. HIV-1 tropism and survival in vertically infected Ugandan infants. J Infect Dis 2008, 197:1382-1388. 10.1086/587492, 18444795.
41. Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, Paxinos EE, Whitcomb JM, Young AM, Donnell D, Mmiro F, Musoke P, Guay LA, Jackson JB, Parkin NT, Petropoulos CJ. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007, 81:7885-7893. 10.1128/JVI.00218-07, 1951291, 17507467.
42. Lihana RW, Khamadi SA, Lwembe RM, Kinyua JG, Muriuki JK, Lagat NJ, Okoth FA, Makokha EP, Songok EM. HIV-1 subtype and viral tropism determination for evaluating antiretroviral therapy options: an analysis of archived Kenyan blood samples. BMC Infect Dis 2009, 9:215. 10.1186/1471-2334-9-215, 2804586, 20040114.
43. Moreno, Clotet, Sarría, Ortega, Leal, Rodriguez-Arrondo, Sánchez-de la R, . Allegro Study Group Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain. HIV Clin Trials 2009, 10:394-402. 10.1310/hct1006-394, 20133270, Allegro Study Group.
44. Shepherd JC, Jacobson LP, Qiao W, Jamieson BD, Phair JP, Piazza P, Quinn TC, Margolick JB. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis 2008, 198:1104-1112. 10.1086/591623, 2753263, 18783316.
45. Simon B, Grabmeier-Pfistershammer K, Rieger A, Sarcletti B, Schmied M, Puchhammer-Stöckl E. HIV co-receptor tropism in antiretroviral treatment-naïve patients newly diagnosed at a late stage of HIV infection. AIDS 2010, 24:2051-2058. 10.1097/QAD.0b013e32833c93e6, 20601851.
46. Genotypic prediction of coreceptor usage. , http://coreceptor.bioinf.mpi-inf.mpg.de/index.php
47. Genotypic prediction of coreceptor usage. , http://fortinbras.us/cgi-bin/fssm/fssm.pl
48. Huang W, Toma J, Fransen S, Stawiski E, Reeves JD, Whitcomb JM, Parkin N, Petropoulos CJ. Co-receptor Tropism Can Be Influenced by Amino Acid Substitutions in the gp41 Transmembrane Subunit of Human Immunodeficiency Virus Type 1 Envelope Protein. J Virol 2008, 82:5584-5593. 10.1128/JVI.02676-07, 2395220, 18353956.
49. Suphaphiphat P, Essex M, Lee TH. Mutations in the V3 stem versus the V3 crown and C4 region have different effects on the binding and fusion steps of human immunodeficiency virus type 1 gp120 interaction with the CCR5 coreceptor. Virology 2007, 360:182-190. 10.1016/j.virol.2006.10.019, 2014721, 17101166.
50. Koito A, Stamatatos L, Cheng-Mayer C. Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. Virology 1995, 206:878-884. 10.1006/viro.1995.1010, 7856100.
51. Carrillo A, Ratner L. Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J Virol 1996, 70:1310-1316. 189949, 8551601.
52. Labrosse B, Treboute C, Brelot A, Alizon M. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. J Virol 2001, 75:5457-5464. 10.1128/JVI.75.12.5457-5464.2001, 114257, 11356952.
53. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. Human immunodeficiency virus type 1 co-receptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006, 80:750-758. 10.1128/JVI.80.2.750-758.2006, 1346864, 16378977.
54. Thielen A, Altmann A, Bogojeska J, Kaiser R, Lengauer T. Estimating evolutionary pathways to CXCR4 usage from cross-sectional data [abstract]. Antivir Ther 2009, 14(Suppl 1):A16.
55. Thielen A, Sichtig N, Kaiser R, Lam J, Harrigan PR, Lengauer T. Improved prediction of HIV-1 coreceptor usage with sequence information from the second hypervariable loop of gp120. J Infect Dis 2010, 202:1435-1443. 10.1086/656600, 20874088.
56. Stawiski E, Huang W, Whitcomb J, Petropoulos C, Coakley E. Amino Acid Changes in gp41 of HIV-1 Associated with Co-receptor Tropism [abstract]. Antivir Ther 2009, 14(Suppl 1):A133.
57. Thielen A, Lengauer T, Harrigan PR, Swenson L, Dong W, McGovern RA, Lewis M, Heera J, Valdez H. Mutation Within GP41 are Correlated With Co-Receptor Tropism but Do Not Substantialy Improve Co-Receptor Usage Prediction. 8th European HIV Drug Resistance Workshop, From basic science to clinical decision making 2010, Italy.
58. Los Alamos HIV Sequence Database. , http://www.hiv.lanl.gov/components/sequence/HIV/search/search.html
59. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997, 25:4876-4882. 10.1093/nar/25.24.4876, 147148, 9396791.
60. Hall TA. BioEdit: A user-friendly biological sequence alignment, editor and analysis program for Windows 95/98 NT. Nucl Acids Symp Ser 1999, 41:95-98.
61. Aquaro S, D'Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, Santoro M, Bertoli A, Mazzotta F, Bonora S, Tozzi V, Bellagamba R, Zaccarelli M, Narciso P, Antinori A, Perno CF. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006, 58:714-722. 10.1093/jac/dkl306, 16891628.
62. Svicher V, Balestra E, VandenbrouckeI, Sarmati L, D'Arrigo R, Van Marck H, Pollicita M, Saccomandi P, Scopelliti F, Cammarota R, Di Santo F, Aquaro S, Stuyver L, Ceccherini-Silberstein F, Andreoni M, Perno C. Ultradeep pyrosequencing and phenotypic analysis to characterize the V3 genetic diversity among HIV-1 primary isolates and their responses to maraviroc [abstract 77]. 7th European HIV Drug Resistance Workshop 2009, Sweden.
63. Svicher V, Aquaro S, D'Arrigo R, Artese A, Dimonte S, Alcaro S, Santoro MM, Di Perri G, Caputo SL, Bellagamba R, Zaccarelli M, Visco-Comandini U, Antinori A, Narciso P, Ceccherini-Silberstein F, Perno CF. Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J Infect Dis 2008, 197:1408-1418. 10.1086/587693, 18419549.
64. Benjamini Y, Hochberg Y. Controlling The False Discovery Rate: A Pratical and Useful Approach to Multiple Testing 1995, 57(1). Journal of Royal Statistical Society, Series B.
65. Svicher V, Alteri C, D'Arrigo R, Laganà A, Trignetti M, Lo Caputo S, Callegaro AP, Maggiolo F, Mazzotta F, Ferro A, Dimonte S, Aquaro S, di Perri G, Bonora S, Tommasi C, Trotta MP, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F. Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev. Antimicrob Agents Chemother 2009, 53:2816-2823. 10.1128/AAC.01067-08, 2704662, 19124665.
66. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, Schuitemaker H. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992, 66:3183-3187. 241084, 1560543.
67. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992, 66:6777-6780. 240176, 1404617.
68. Svicher V, Cammarota R, Artese A, D'Arrigo R, Parisi S, Zazzi M, Antinori A, Angarano G, Nozza S, Perno CF, . Oscar Study Group New V3-genetic Signatures Modulate Co-receptor Usage in vivo and the Interaction with CCR5 N-terminus. Program and Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections San Francisco, CA 2010, Foundation for Retrovirology and Human Health, Alexandria, VA, USA, Oscar Study Group.
69. Leal E, Janini M, Diaz RS. Selective pressures of human immunodeficiency virus type 1 (HIV-1) during pediatric infection. Infect Genet Evol 2007, 7:694-707. 10.1016/j.meegid.2007.07.008, 17719854.
70. Lemey P, Kosakovsky Pond SL, Drummond AJ, Pybus OG, Shapiro B, Barroso H, Taveira N, Rambaut A. Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics. PLoS Comput Biol 2007, 3:e29. 10.1371/journal.pcbi.0030029, 1797821, 17305421.
71. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999, 73:10489-10502. 113104, 10559367.
72. Yang W, Bielawski JP, Yang Z. Widespread adaptive evolution in the human immunodeficiency virus type 1 genome. J Mol Evol 2003, 57:212-221. 10.1007/s00239-003-2467-9, 14562964.
73. Ross HA, Rodrigo AG. Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. J Virol 2002, 76:11715-11720. 10.1128/JVI.76.22.11715-11720.2002, 136752, 12388731.
74. Williamson S. Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression. Mol Biol Evol 2003, 20:1318-1325. 10.1093/molbev/msg144, 12777505.
75. Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 1991, 65:4832-4838. 248941, 1714520.
76. Dimmock NJ. The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: a lesson in epitope analysis. Rev Med Virol 2005, 15:365-381. 10.1002/rmv.476, 16106492.
77. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008, 72:54-84. 10.1128/MMBR.00020-07, 2268283, 18322034.
78. Hrin R, Montgomery DL, Wang F, Condra JH, An Z, Strohl WR, Bianchi E, Pessi A, Joyce JG, Wang YJ. Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. AIDS Res Hum Retroviruses 2008, 24:1537-1544. 10.1089/aid.2008.0129, 19102685.
79. Cleveland SM, McLain L, Cheung L, Jones TD, Hollier M, Dimmock NJ. A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. J Gen Virol 2003, 84(3):591-602. 10.1099/vir.0.18630-0, 12604810.
80. Cheung L, McLain L, Hollier MJ, Reading SA, Dimmock NJ. Part of the C-terminal tail of the envelope gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 is exposed on the surface of infected cells and is involved in virus-mediated cell fusion. J Gen Virol 2005, 86(1):131-138. 10.1099/vir.0.80439-0, 15604440.
81. Prabakaran P, Dimitrov AS, Fouts TR, Dimitrov DS. Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors. Adv Pharmacol 2007, 55:33-97.
82. Merat R, Raoul H, Leste-Lasserre T, Sonigo P, Pancino G. Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1. J Virol 1999, 73:5698-5706. 112629, 10364320.
83. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, Guo Y, Kajumo F, Anselma DJ, Maddon PJ, Olson WC, Moore JP. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000, 74:627-643. 10.1128/JVI.74.2.627-643.2000, 111582, 10623724.
84. Maerz AL, Drummer HE, Wilson KA, Poumbourios P. Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association. J Virol 2001, 75:6635-6644. 10.1128/JVI.75.14.6635-6644.2001, 114387, 11413331.
85. Quintana FJ, Gerber D, Kent SC, Cohen IR, Shai Y. HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. J Clin Invest 2005, 115:2149-2158. 10.1172/JCI23956, 1172229, 16007266.
86. Chen CH, Greenberg ML, Bolognesi DP, Matthews TJ. Monoclonal antibodies that bind to the core of fusion-competent gp41. AIDS Res Hum Retroviruses 2000, 16:2037-2041. 10.1089/088922200750054765, 11153086.
87. Vincent N, Kone A, Chanut B, Lucht F, Genin C, Malvoisin E. Antibodies purified from sera of HIV-1-infected patients by affinity on the heptad repeat region 1/heptad repeat region 2 complex of gp41 neutralize HIV-1 primary isolates. AIDS 2008, 22:2075-2085. 10.1097/QAD.0b013e3283101260, 18832871.
88. Park EJ, Quinnan GV. Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. J Virol 1999, 73:5707-5713. 112630, 10364321.
89. Rodrigo AG. Dynamics of syncytium-inducing and non-syncytium-inducing type 1 human immunodeficiency viruses during primary infection. AIDS Res Hum Retroviruses 1997, 13:1447-1451. 10.1089/aid.1997.13.1447, 9390743.
90. Leavitt M, Park EJ, Sidorov IA, Dimitrov DS, Quinnan GV. Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120. J Virol 2003, 77:560-570. 10.1128/JVI.77.1.560-570.2003, 140585, 12477860.
91. Hollier MJ, Dimmock NJ. The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function. Virology 2005, 337:284-296. 10.1016/j.virol.2005.04.015, 15913700.
92. Tan K, Liu J, Wang J, Shen S, Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci USA 1997, 94:12303-12308. 10.1073/pnas.94.23.12303, 24915, 9356444.
93. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-430. 10.1038/387426a0, 9163431.
94. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 8:263-273.
95. Shi W, Bohon J, Han DP, Habte H, Qin Y, Cho MW, Chance MR. Structural characterization of HIV gp41 with the membrane-proximal external region. J Biol Chem 2010, 285:24290-24298. 10.1074/jbc.M110.111351, 20525690.
96. Gangupomu VK, Abrams CF. All-atom models of the membrane-spanning domain of HIV-1 gp41 from metadynamics. Biophys J 2010, 99:3438-3444. 10.1016/j.bpj.2010.09.054, 21081093.
97. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659. 10.1038/31405, 9641677.
98. Finzi A, Xiang SH, Pacheco B, Wang L, Haight J, Kassa A, Danek B, Pancera M, Kwong PD, Sodroski J. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell 2010, 37:656-667. 10.1016/j.molcel.2010.02.012, 2854584, 20227370.
99. Xiang SH, Finzi A, Pacheco B, Alexander K, Yuan W, Rizzuto C, Huang CC, Kwong PD, Sodroski J. A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. J Virol 2010, 84:3147-3161. 10.1128/JVI.02587-09, 2838131, 20089638.
100. Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, Scarlatti G, Longhi R, Berger EA, Burastero SE. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 2005, 79:6957-6968. 10.1128/JVI.79.11.6957-6968.2005, 1112133, 15890935.
101. Sander O, Sing T, Sommer I, Low AJ, Cheung PK, Harrigan PR, Lengauer T, Domingues FS. Structural descriptors of gp120 V3 loop for the prediction of HIV-1 co-receptor usage. PLoS Comput Biol 2007, 3:e58. 10.1371/journal.pcbi.0030058, 1848001, 17397254.
102. Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci USA 2009, 106:5318-5323. 10.1073/pnas.0811713106, 2664029, 19289833.
103. Pfaff JM, Wilen CB, Harrison JE, Demarest JF, Lee B, Doms RW, Tilton JC. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J Virol 2010, 84:6505-6514. 10.1128/JVI.00374-10, 2903254, 20410277.